Meeting user needs with a new product category: Considerations for the future of vaginal rings

Saumya RamaRao, Heather Clark and Naomi Rijo,
Population Council
NURHT New Horizons Panel, March 20, 2018
The promise of vaginal rings

- Sustained release of active agent
- Vaginal application reduces side-effects
- Under woman’s control
- Does not require medical equipment
- Can be provided by many HCP cadres
- Potential for many sources of supply
- Potential for MPT ring
## Rings on or close to market

<table>
<thead>
<tr>
<th>Ring</th>
<th>Indication</th>
<th>Institution/company</th>
<th>Regulatory status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progering®</td>
<td>Contraception for lactating women</td>
<td>ICCR</td>
<td>Available in Latin America</td>
</tr>
<tr>
<td>NuvaRing®</td>
<td>Contraception</td>
<td>Merck</td>
<td>Available high/middle income countries</td>
</tr>
<tr>
<td>NES/EE</td>
<td>Contraception</td>
<td>Pop Council</td>
<td>NDA filed</td>
</tr>
<tr>
<td>Fertiring®</td>
<td>Hormonal therapy</td>
<td>ICCR / Population Council</td>
<td>Available in Latin America</td>
</tr>
<tr>
<td>Estring®</td>
<td>Hormonal therapy</td>
<td>Pfizer</td>
<td>Marketed</td>
</tr>
<tr>
<td>Femring®</td>
<td>Hormonal therapy</td>
<td>Warner Chilcott</td>
<td>Marketed</td>
</tr>
</tbody>
</table>
Rings in development

HIV prevention rings
• Dapivirine under Article 58 review of EMA

Pregnancy prevention
• Nestorone/Estradiol for reduced VTEs

Multipurpose Rings for HIV/STI/Pregnancy prevention
• 4 rings in Phase I
• 5 rings in preclinical phase
A closer look at Population Council-developed rings
Progesterone Vaginal Ring (PVR)

- For **postpartum lactating** women in first year postpartum
- Natural progesterone hormone safe for baby and mother
- Used continuously for 3 months
- **Four rings** can be used successively for up to 1 year postpartum
- Approved in 8 Latin American countries (registration planned for Mexico, Brazil, Nigeria, Senegal, Kenya, India)
Nestorone®/Ethynyl Estradiol Contraceptive Vaginal Ring (NES/EE CVR)

For non-lactating women

1 ring used for 1 year

Removed every 3 weeks for menses

No cold chain required

Undergoing FDA review
Next steps for PVR and NES/EE rings

PVR
- Register in Nigeria, Senegal, Kenya and India
- Market entry activities in Nigeria

NES/EE
- Secure FDA approval
Future considerations for rings
Social and programmatic

1. User preference
2. Platforms to reach users
3. Support for continuing use
Health Policy and Program Analysis

- Description of package of services to support introduction
- Successes and challenges of past introduction
- Pathways to scale
- Cost and financing
Market analysis

1. Viability of the market
2. Sustaining the market
3. Market Shaping
Biomedical

1. Development of MPTs
2. Incorporation of human centered design
3. Effects on environment
Thank You and Acknowledgments

DONOR SUPPORT
USAID
The Bill and Melinda Gates Foundation
NICHD

MINISTRIES OF HEALTH
India, Kenya, Nigeria, Senegal